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Background and objective: Interaction between pharmaceutical sales representatives (PSRs) and general
practitioners (GPs) may have an adverse impact on GP prescribing and therefore may be ethically
questionable. This study aimed to evaluate the interactions between PSRs and GPs in an Australian general
practice, and develop and evaluate a policy to guide the interaction.
Methods: Doctors’ prescribing, diaries, practice promotional material and samples were audited and a staff
survey undertaken. After receiving feedback, the staff voted on practice policy options. The resulting policy
was evaluated 3 and 9 months.
Results: Prior to the intervention, GPs spent on average 40 min/doctor/month with PSRs. There were 239
items of promotional material in the practice and 4660 tablets in the sample cupboard. These were reduced
by 32% and 59%, respectively, at 3 months after policy adoption and the reduction was sustained at
9 months. Vioxx was the most common drug name in promotional material. Staff adopted a policy of reduced
access to PSRs including: reception staff not to make appointments for PSRs or accept promotional material;
PSRs cannot access sample cupboards; GPs wishing to see PSRs may do so outside consulting hours. At 3 and
9 months, most staff were satisfied with the changes. Promotional items/room were not significantly reduced
at 3 months (24.0 items/room ; 95% CI 26.61 to 21.39; p = 0.066) or 9 months (22.63 items/room; 95%
CI 25.86 to 0.60; p = 0.24). Generic prescribing significantly increased at 3 months (OR 2.28, 95% CI 1.31
to 3.86; p = 0.0027) and 9 months (OR 2.07, 95% CI 1.13 to 3.82; p = 0.016).
Conclusion: There was a marked reduction in interactions with PSRs with majority staff satisfaction and
improved prescribing practices. The new policy will form part of the practice’s orientation package. Reception
staff give PSRs a letter explaining the policy. It is hoped that the extra 40 min/doctor of consulting time
translates into more time with patients and time to evaluate more independent sources of drug information.
P
harmaceutical sales representatives (PSRs) have an impor-
tant role in general practice. Studies from several countries
indicate that 80–95% of doctors see PSRs regularly.1 In
Australia, pharmaceutical companies spend on average
approximately $A16 548 (£6913) on promotion per general
practitioner (GP) per year. This includes $A10 921 (£4562) for
detailing.2 3 GPs in Birmingham, UK, have often used drug
company information as their sole source of information for
new drugs.4 Concerns have been described in the literature
about the role of PSRs in general practice. PSRs are usually
more informative about the benefits than the harms and costs
of drugs, and they often make statements not in accord with
approved product information.5 6 A US study found that 11% of
statements that PSRs made were inaccurate, and all of these
were favourable to their drug. None of the 14% of statements
made about competitors’ drugs were favourable, but they were
all accurate. A survey of the 27 physicians who participated in
this study found that 74% did not recall any false statement
made by PSRs.7
Caamano et al found that the cost of prescribing increased
remarkably for GPs who gave more credence to information
from PSRs.8 Mizik et al quantified the effect of PSRs on doctors’
prescribing using data from pharmaceutical companies in the
USA. They found that for three unnamed drugs, the mean
number of PSR visits to induce one prescription was 0.64 visits
for drug A, 3.1 visits for drug B and 6.5 visits for drug C.9
Although many GPs deny that PSRs adversely influence their
prescribing, interactions with PSRs are associated with unne-
cessary prescribing, prescribing inappropriately,10 11 decreased
prescribing of generic drugs12 and increases in the cost of
prescribing.13 14 Gifts, such as pens, posters and tear-off pads,
which also serve as promotional material in general practice,
have been seen as desirable by GPs in New Zealand.15 Most GPs
deny that gifts influence their prescribing yet would not see
PSRs as often if they did not offer promotional materials.13 GPs
who accept samples from PSRs are more likely to be early
prescribers of new drugs.16 Acceptance of samples may also lead
to GPs’ choosing from the limited range of samples available
rather than prescribing their first choice.17 Storage of samples
may also lead to expiry and waste problems.18
Until 2004, PSRs had unrestricted access to the staff at the
Inala Health Centre General Practice in Brisbane, Australia, and
often provided lunch at weekly journal club meetings. GPs saw
PSRs individually and accepted sample medications passively.
There were no policies about PSRs, their gifts or drug samples.
This paper reports a quality improvement, action research
approach to develop and implement a new policy regarding
relationships with PSRs and to evaluate its impact.
METHODS
The Inala Health Centre General Practice is situated in a socially
disadvantaged part of Brisbane, Australia. It is an academic
general practice with seven part-time GPs, three practice
nurses, three regular reception staff and a practice manager.
In 2004 we audited doctors’ patient appointment lists, doctors’
prescribing, practice promotional material and samples, and
conducted a staff survey. Over the following year, we presented
the results of the audits and surveys to practice staff, who were
then asked to vote anonymously for a range of practice policy
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options on interactions with PSRs and acceptance of samples. The
impact of the new policy was evaluated with surveys at 3 months
and 9 months after the policy was adopted.
Situation analysis
We retrospectively examined doctors’ patient appointment
diaries chosen at random for a 1-month period to measure
the number and length of booked PSR visits. A random week
was chosen to audit doctors’ prescribing. Promotional items in
the practice left by PSRs were counted and categorised by room,
type of item and drug. All 14 staff participated anonymously in
the survey in November 2004 and all except one returned the
completed questionnaire. Staff were asked about perceived pros
and cons of seeing PSRs and whether they would like to spend
more, the same or less time with PSRs.
Policy adoption
Results of the audit of doctors’ patient appointment lists,
promotional material and samples were fed back to staff along
with the survey responses from their colleagues. We compiled
the data using Excel and staff were provided the data in
aggregate form to maintain anonymity. Results were cate-
gorised by the area in which staff worked. We then asked staff
to vote anonymously on three policy options: more, less or the
same access to PSRs. Staff were also given the option to write
their own policy.
The voting results were discussed at the practice meeting. The
option with the most votes was adopted, and practical
implementation of the new policy was discussed.
Outcome evaluation
At 3 months and 9 months after the policy came into practice,
we conducted a staff survey on their level of satisfaction with
changes resulting from the new policy. The survey also included
questions about time spent with PSRs and the pros and cons of
the policy. Objective measures included: doctors’ prescribing
(including generic prescribing), promotional material, samples
in the drug cupboard and time booked for PSRs. Tests of
statistical significance on the non-parametric outcome of
number of promotional items per room at the three different
time periods were undertaken using EpiInfo (version 3.3.2).
Confidence intervals and x2 statistics for comparisons of generic
prescribing proportions at the three time points were calculated
using OpenEpi (http://www.openepi.com/Menu/OpenEpi
Menu.htm; accessed 14 March 2007).
RESULTS
Situation analysis
During 1 month in 2004, 16 appointments with PSRs at an
average of 16 min each were set aside by three of the seven
doctors in the practice. Doctors reported 12 corridor visits with
PSRs at 2 min each (table 1) This amounts to approximately
5 hours of doctors’ time spent with PSRs in 1 month (40 min/
doctor/month). In our practice this equates to approximately
$A670 (£280) in earnings, and 18 patients cared for.
There were 239 items containing promotional material from
PSRs in the practice at an average of 12.6 items per room. Over
half of this promotional material was in doctors’ rooms (148
items) at an average of 29.6 items per room, with the next most
concentrated area being reception with 28 items (table 1).
There were two items of promotional material in the waiting
room. The only rooms free of promotional material in the
practice were the isolation room and the toilet. Vioxx was the
most common drug name found in promotional material
followed by Fosamax, Zoloft, Avandia and Voltaren. The most
common items were small tear-off writing pads, followed by
body part models, pens, cups and posters. We estimated the
total value of promotional items in the practice to be $A3700
(£1545). The average cost of promotional items was $A12 (£5)
ranging from 50c (20p) for a tear-off writing pad to $A55 (£23)
for a model of a heart. The sample cupboard audit revealed
4660 items (table 1). Doctors were prescribing at 0.99 scripts
per patient encounter with 4% of scripts being generic (table 1).
Regarding time available to see PSRs, the average staff
response was neutral. Doctors and nurses tended to prefer
spending less time with PSRs, whereas administrative staff had
a preference for more time with PSRs (table 2).
Perceived benefits of seeing PSRs
Doctors perceived benefits of learning about new drugs and
acquiring samples. Nursing staff cited borrowing equipment.
Administrative staff cited free samples, pens and notepads.
Table 1 Impact of the new policy on the interactions between general practitioners and






Doctor visits with PSRs in 1 month
PSR visits booked in doctors’ diaries 16 0 0
Reported corridor visits 12 2 0
No. of promotional items (mean/room) at the Inala Health Centre General Practice
Doctors rooms (n = 5) 148 (29.6) 112 (22.4) 120 (24)
Total administration area (n = 2) 38 (19) 27 (13.5) 26 (13)
Total nursing area (n = 7) 25 (8.3) 14 (2) 37 (5.3)
Total other areas (n = 5) 28 (5.6) 10 (2) 6 (1.2)
Total 239 (12.6) 163 (8.6)* 189 (10.0)
Sample cupboard items (tablets/capsules/tubes/bottles) 4660 1902 1389
Prescribing patterns (based on 1 week of practice prescribing data at each time period)
Patient encounters 547 504 530
Number of prescriptions (total) 542 464 285
Prescriptions per patient encounter 0.99 0.92 0.54
Generic prescriptions (% of total prescriptions) 4 8.6` 8.11
*3-month postintervention audit compared with preintervention: 276 items (24.0 items/room; 95% CI 26.61 to
21.39); Kruskal–Wallis H test = 14.7, df = 8, p = 0.066.
9-month postintervention audit compared with preintervention: 250 items (22.63 items/room; 95% CI25.86 to 0.60);
Kruskal–Wallis H test = 13.9, df = 11, p = 0.24.
`3-month postintervention audit compared with preintervention: odds ratio 2.28 (95% CI 1.31 to 3.86); x2 test = 8.99,
df = 1, p = 0.0027.
19-month postintervention audit compared with preintervention: odds ratio 2.07 (95% CI 1.13 to 3.82); x2 test = 5.84,
df = 1, p = 0.016.
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Perceived disadvantages of seeing PSRs
All staff were concerned that time spent with PSRs could be
better spent. Doctors were also concerned about quality of
information and feeling pressured to prescribe. Administrative
staff were concerned about PSRs being pushy at reception.
Policy adoption
Most of the practice staff (9/11) voted for a policy of reduced
access to PSRs. One staff member voted for more access to PSRs
and one wrote a personal policy. No-one voted to maintain the
status quo. Staff met, discussed the vote, and the resulting
policy reduced access to PSRs. The policy states that reception
staff are not to make appointments for PSRs nor accept
promotional material. PSRs wishing to alert doctors to new
products should place written material in a box which a doctor
would go through each month. Doctors wishing to see PSRs are
to initiate contact and make appointments outside patient
consulting hours. PSRs are not to be invited to lunch time
meetings without prior approval of all relevant staff, and they
no longer have access to the sample cupboard. Doctors desiring
particular samples need to approach the relevant PSR.
Outcomes
Staff turnover was low during the period of this study. The
numbers of staff of all types remained stable over the course of
the study.
At 3 months after policy introduction
All staffing areas were satisfied on average with the impact of
the new policy. Most staff indicated they spent less time with
PSRs (table 3). Overall promotional material and samples were
reduced by 32% and 59%, respectively. Promotional material per
room also fell but the difference was not statistically
significant. Prescriptions per patient encounter fell by a small
amount to 0.92 and generic prescriptions increased significantly
from 4% to 8.6% (see table 1).
At 9 months after policy introduction
Staff were satisfied on average with the impact of the new
policy at 9 months though reception staff were neutral on
average. At 9 months all staff indicated they spent less time
with PSRs (table 3). There were no PSR visits booked into the
patient appointment diaries and no reported corridor visits
(table 1). Overall promotional material had increased 14% from
the 3-month evaluation but was still 21% less that prior to the
policy change. Reductions in the mean number of promotional
items per room did not reach statistical significance (table 1).
Sample numbers fell a further 27% from the 3-month
evaluation and were now 70% less than before policy
implementation. Prescriptions per patient encounter fell shar-
ply to 0.54 and the increase in generic prescribing from
preintervention was maintained at 8.1% (p = 0.016 compared
with preintervention (see table 1).
Qualitative responses to survey questions
Staff responses were qualitatively similar at 3 and 9 months
after the policy was adopted. A summary of responses at these
two timepoints have been combined below.
Benefits of the policy
Doctors reported less junk mail, no pressure to see PSRs and no
intrusive calls from reception. Nurses reported spending less
time administering the sample cupboard and finding doctors to
sign for samples. Administrative staff reported not having to
deal with the PSR appointment planner and not having to find
doctors to sign for samples. All staff noted that PSRs no longer
frequented the practice corridor.
Disadvantages of the policy
Doctors were concerned about the lack of appropriate samples.
Nurses did not raise any concerns. Administrative staff were
concerned they had less stationery, were not receiving as much
‘‘free stuff’’ and had trouble getting a doctor to go through the
box with PSR information.
DISCUSSION
The action research process was followed by a marked
reduction in interactions with PSRs. Most staff indicated they
were satisfied with the changes at 3 and 9 months. Because our
study was not a randomised controlled trial we cannot rule out
the possibility that confounding factors contributed to this
change. However, we are not aware of any factors that could
have made such a large difference other than our intervention.
Attitudes towards pharmaceutical promotion are changing
slowly, but we are not aware of any such dramatic behavioural
change elsewhere in Australian general practice. There were
possibly several reasons why the practice chose to reduce
interactions with PSRs instead of increasing them or main-
taining the status quo. The main reason was probably that at
baseline most of the practice’s GPs wanted less interactions
with PSRs (table 2). The intervention may have worked by
making change easier and by putting the issue at the top of the
agenda. The other GPs in the practice were content with the
status quo at the beginning but decided to reduce interactions
with PSRs as the quality improvement process continued. It
seemed that for nurses in the practice, interactions with PSRs
Table 2 Preintervention preferences* for amount






Doctors (n = 6) 0 2 3 1
Nurses (n = 3) 0 1 1 1
Administration (n = 4) 2 0 1 1
Total IHCGP staff (n = 13) 2 3 5 3
IHCGP, Inala Health Centre General Practice.
*Regarding time available to see PSRs, should it be more, the
same or less?











Satisfaction following policy adoption*
Medical 4 4 1.22 4.25 4 0.5
Nursing 4.67 5 0.58 5 5 0
Administration 4 4 0.82 3.3 3 0.58
All staff 4.17 4 0.94 4.11 4 0.78
Time spent with PSRs following policy adoption
Medical 20.8 21 0.45 21 21 0
Nursing 21 21 0 21 21 0
Administration 20.75 21 0.5 21 21 0
All staff 20.83 21 0.5 21 21 0
*Level of satisfaction following policy adoption: 5 = very satisfied, 4 =
satisfied, 3 = neutral, 2 = dissatisfied, 1 = very dissatisfied.
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meant a lot of work and little gain. They were consistently the
most satisfied group with reduction in interactions with PSRs.
Reception staff benefited from practice interactions with PSRs
but were largely persuaded by arguments that practice/PSR
interactions were not always in the best interests of patients.
Elements crucial for the development and adoption of the new
policy included involving all staff and maintaining anonymity
at all stages of survey, data presentation and policy adoption.
This interprofessional teamwork is an important factor in the
success of quality improvement activities.19 Good teamwork and
a sense of personal involvement in the quality improvement
process has been associated with the success of other quality
improvement activities in primary care.20 Our new practice
policy allows doctors who wish to maintain relationships with
PSRs to do so. However, it is the doctor and not the PSR who
actively initiates the contact. Key outcomes 3 months after the
implementation of this new policy included approximately 5 h
more consulting time for patients each month, a reduction in
PSR corridor visits, a 32% reduction in promotional material
and a 59% decrease in items in the sample cupboard. These
reductions were sustained 9 months after policy introduction
with no scheduled or corridor interactions between GPs and
PSRs. We anticipate that this reduction will reduce the
exposure of GPs to inaccurate drug information.7 The findings
in this study of a reduction in prescriptions per patient
encounter and a significant increase in generic prescriptions
are consistent with reports indicating that contact between GPs
and PSRs increases the cost of GP prescribing.13 14
Promotional material had increased slightly at 9 months but
was still 21% lower than prior to the policy introduction.
Sample numbers continued to fall and by 9 months were 70%
lower than before the policy introduction. We expect this to
reduce inappropriate changes in GP medication choice owing to
sample availability17 and reduce wastage of medications.18 The
nurses were happy about having less work to do administering
the sample cupboard.
Some have argued that doctors should decline any contact
with PSRs because they have concluded that such contact is not
in the best interests of patients.21 22 Through this quality
improvement process, it was clear that although the Inala
Health Centre General Practice staff were willing to reduce
interactions between the practice and PSRs, many did not want
to stop all interactions with PSRs. However, it may be possible
to achieve a policy of no contact with PSRs by using an iteration
of this quality improvement process if it incorporates convin-
cing evidence that contact with PSRs does more harm than
good for patients.
Promotional material from PSRs was not evenly distributed
through the practice. It was most heavily concentrated in
doctors’ consulting rooms presumably because that is where
PSR visits and prescribing occur. Reception also had a high
concentration of promotional material and the reasons for this
are explained in a guidebook for PSRs: reception staff are
‘‘incredibly critical in obtaining access, information, assistance
and even a smile when things are not going well. Spend a few
moments to develop this critical resource. Remember they have
a job to do, but working together can enhance both. A warm
hello, a helpful tip, or even a small box of candy can go a very
long way.’’23 It is of concern that the medication most
frequently advertised via promotional material was Vioxx
(rofecoxib). Rofecoxib was withdrawn by its manufacturer
11 months after the initial assessment period.
The Inala Health Centre General Practice is publicly funded
and staffed by academic GPs. Our findings may not apply to
non-academic general practices. Staff turnover, albeit low, may
have been a confounding factor for outcomes in this study.
Staff were also aware that they were being researched as part of
a quality improvement process. Consequently, a Hawthorne
effect may have contributed to the results. One author (GS) is a
doctor at this practice and did not participate in the staff
surveys. This author did not see any PSRs during the study
periods but worked in one of the rooms where promotional
material was audited and contributed to prescribing data at the
three time periods. Further research in this area may involve a
randomised controlled trial of a number of practices using this
type of quality improvement process as the intervention. This
would allow examination of confounding factors such as staff
turnover, academic interest, type of practice, patient mix,
seasonality and the Hawthorne effect.
The new policy will form part of our GP trainee/new staff
orientation package. Reception staff give a letter explaining the
policy changes to the PSRs. The authors are not aware of other
published quality improvement research in the area of
interactions between PSRs and doctors. This is the only
published intervention the authors are aware of where the
impact of the interaction between PSRs and GPs has been
reduced. We expect that the reduced time spent with PSRs will
translate into more time spent with patients and/or used to
evaluate more independent sources of drug information. This
should continue to translate into improved prescribing practices
for the benefit of patients.
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indings from an Australian study suggest that measures are needed to stop patients leaving
hospital emergency departments (EDs) without seeing a doctor, after estimating that about
half of them warranted an examination, some of whom may not have other options for
obtaining health care. This is the first large scale study in Australia to ascertain how such
patients fare, assessing over 450 patients.
Most likely to walk out were patients with a ‘‘potentially serious’’ problem or a ‘‘less urgent’’
problem. Nevertheless, almost two thirds of those who left contacted other health agencies
during the following week: 57% visited general practitioners, who triaged a quarter as having
potentially life threatening disease. In all, 13% of all patients who walked out revisited EDs
within seven days afterwards, and 5% were admitted; 8% accessed no services during this time.
Determining such patients’ exact needs might permit service improvements to reduce
walkouts, the researchers think. Their data already show that those who leave after triage are
typically young (,30 years), parents with young children, and are dissatisfied with waiting
time. Overcrowding in the department and night time attendance were also linked to walking
out, as elsewhere.
The study attempted to follow up by telephone 1272 patients identified from 14 741patient
registrations as walking out of one ED in a teaching hospital in Sydney during four months in
2003.
Only a few studies have tried to ascertain what happens to patients who walk out of EDs—an
important basis for assessing healthcare delivery and future planning.
m Mohsin M, et al. Emergency Medicine Journal 2007;24:175–179.
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